Center of Molecular Medicine Central European Institute of Technology Masaryk University Brno Czechia

Centre for Haemato Oncology Barts Cancer Institute Queen Mary University of London London United Kingdom

ClinSciNet The Clinician Scientist Network Münsingen Germany

Department of Haemato Oncology Barts Health NHS Trust St Bartholomew's Hospital London United Kingdom

Department of Internal Medicine Hematology and Oncology University Hospital Brno Masaryk University Brno Czechia

Zobrazit více v PubMed

Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program (2010) 2010:481–8. doi: 10.1182/asheducation-2010.1.481 PubMed DOI

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. . iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood (2018) 131:2745–60. doi: 10.1182/blood-2017-09-806398 PubMed DOI

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. . Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2021) 32:23–33. doi: 10.1016/j.annonc.2020.09.019 PubMed DOI

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. . Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv (2022) 6:3440–50. doi: 10.1182/bloodadvances.2021006434 PubMed DOI PMC

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. . Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med (2018) 379:2517–28. doi: 10.1056/NEJMoa1812836 PubMed DOI PMC

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. . First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: Final analysis of the randomized, phase III iLLUMINATE trial. Haematologica (2022) 107:2108–20. doi: 10.3324/haematol.2021.279012 PubMed DOI PMC

Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O’Brien S, Barrientos J, et al. . Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial. Blood (2022) 140:112–20. doi: 10.1182/blood.2021014960 PubMed DOI PMC

Hillmen P, Bloor A, Broom A, Young M, Kennedy B, Walewska R, et al. . Ibrutinib plus rituximab is superior to FCR in previously untreated CLL: Results of the phase III NCRI FLAIR trial. Blood (2021) 138:642. doi: 10.1182/blood-2021-152319 DOI

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. . Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia. Leukemia (2022) 36:1171–5. doi: 10.1038/s41375-021-01485-x PubMed DOI PMC

Al-Sawaf O, Zhang C, Lu T, Liao MZ, Panchal A, Robrecht S, et al. . Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: Extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol (2021) 39:4049–60. doi: 10.1200/JCO.21.01181 PubMed DOI PMC

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. . Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med (2018) 378:1107–20. doi: 10.1056/NEJMoa1713976 PubMed DOI

Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin MD, et al. . Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid (2022) 1. doi: 10.1056/EVIDoa2200006 PubMed DOI

Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. . Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: Primary analysis of the CAPTIVATE FD cohort. Blood (2022) 139:3278–89. doi: 10.1182/blood.2021014488 PubMed DOI

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. . Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: Results from the full population of a phase II pivotal trial. J Clin Oncol (2018) 36:1973–80. doi: 10.1200/JCO.2017.76.6840 PubMed DOI

Rogers KA, Huang Y, Ruppert AS, Abruzzo LV, Andersen BL, Awan FT, et al. . Phase II study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2020) 38:3626–37. doi: 10.1200/JCO.20.00491 PubMed DOI PMC

Huber H, Edenhofer S, von Tresckow J, Robrecht S, Zhang C, Tausch E, et al. . Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood (2022) 139:1318–29. doi: 10.1182/blood.2021013208 PubMed DOI

Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, et al. . Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: A single-arm, open-label, phase 2 study. Lancet Oncol (2021) 22:1391–402. doi: 10.1016/S1470-2045(21)00455-1 PubMed DOI

Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, et al. . Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Haematol (2021) 8:e879–e90. doi: 10.1016/S2352-3026(21)00307-0 PubMed DOI PMC

Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. . Pirtobrutinib in relapsed or refractory b-cell malignancies (BRUIN): A phase 1/2 study. Lancet (2021) 397:892–901. doi: 10.1016/S0140-6736(21)00224-5 PubMed DOI

Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, et al. . Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia. J Hematol Oncol (2022) 15:166. doi: 10.1186/s13045-022-01386-1 PubMed DOI PMC

Zhang D, Harris HM, Chen J, Judy JT, James G, Kelly A, et al. . NRX-0492 degrades wildtype and C481 mutant BTK and demonstrates in vivo activity in CLL patient derived xenografts. Blood (2022). doi: 10.1182/blood.2022016934 PubMed DOI PMC

Deng J, Paulus A, Fang DD, Manna A, Wang G, Wang H, et al. . Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy. Clin Cancer Res (2022) 28:5455–68. doi: 10.1158/1078-0432.CCR-21-4037 PubMed DOI

Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med (2020) 383:498–500. doi: 10.1056/NEJMc2005943 PubMed DOI PMC

Allan JN, Shanafelt T, Wiestner A, Moreno C, O’Brien SM, Li J, et al. . Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: A pooled analysis from four clinical trials. Br J Haematol (2022) 196:947–53. doi: 10.1111/bjh.17984 PubMed DOI PMC

Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. . Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med (2019) 380:2225–36. doi: 10.1056/NEJMoa1815281 PubMed DOI

Ghia P, Pluta A, Wach M, Lysak D, Kozak T, Simkovic M, et al. . ASCEND: Phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol (2020) 38:2849–61. doi: 10.1200/JCO.19.03355 PubMed DOI

Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, et al. . Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion. Haematologica (2020) 106:2354–63. doi: 10.3324/haematol.2020.259432 PubMed DOI PMC

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, et al. . Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med (2022). doi: 10.1056/NEJMoa2211582 PubMed DOI

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, et al. . Ibrutinib treatment for first-line and Relapsed/Refractory chronic lymphocytic leukemia: Final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res (2020) 26:3918–27. doi: 10.1158/1078-0432.CCR-19-2856 PubMed DOI PMC

Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, et al. . Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol (2019) 94:1353–63. doi: 10.1002/ajh.25638 PubMed DOI PMC

Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, et al. . Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood (2019) 133:1011–9. doi: 10.1182/blood-2018-10-879429 PubMed DOI PMC

Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al. . Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood (2019) 133:1205–16. doi: 10.1182/blood-2018-09-873083 PubMed DOI PMC

Thompson PA, O’Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, et al. . Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer (2015) 121:3612–21. doi: 10.1002/cncr.29566 PubMed DOI PMC

Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K, et al. . The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood (2021) 138:2372–82. doi: 10.1182/blood.2020010536 PubMed DOI

Malcikova J, Pavlova S, Kunt Vonkova B, Radova L, Plevova K, Kotaskova J, et al. . Low-burden TP53 mutations in CLL: Clinical impact and clonal evolution within the context of different treatment options. Blood (2021) 138:2670–85. doi: 10.1182/blood.2020009530 PubMed DOI PMC

Gango A, Alpar D, Galik B, Marosvari D, Kiss R, Fesus V, et al. . Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. Int J Cancer (2020) 146:85–93. doi: 10.1002/ijc.32502 PubMed DOI

Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, et al. . Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv (2017) 1:715–27. doi: 10.1182/bloodadvances.2016003632 PubMed DOI PMC

Tausch E, Furstenau M, Robrecht S, Yosifov DY, Mertens D, Gregor M, et al. . Genetic markers and front line FCR/BR vs. rve, gve and give treatment - outcome results from the CLL13/GAIA trial. Blood (2022) 140:839–41. doi: 10.1182/blood-2022-163775 DOI

Niemann CU, Moreno C, Owen C, Follows GA, Benjamini O, Janssens A, et al. . Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): The glow study. Blood (2022) 140:228–30. doi: 10.1182/blood-2022-156070 DOI

Munir T, Bloor A, Pettitt A, Patten PEM, Forconi F, Schuh A, et al. . Combination of ibrutinib plus venetoclax with MRD-driven duration of treatment results in a higher rate of MRD negativity in IGHV unmutated than mutated CLL: Updated interim analysis of FLAIR study. Blood (2022) 140:231–33. doi: 10.1182/blood-2022-170463 DOI

International CLLIPIwg . An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol (2016) 17:779–90. doi: 10.1016/S1470-2045(16)30029-8 PubMed DOI

Kurtz DM, Esfahani MS, Scherer F, Soo J, Jin MC, Liu CL, et al. . Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell (2019) 178:699–713 e19. doi: 10.1016/j.cell.2019.06.011 PubMed DOI PMC

Ahn IE, Tian X, Ipe D, Cheng M, Albitar M, Tsao LC, et al. . Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: Development and validation of a four-factor prognostic model. J Clin Oncol (2021) 39:576–85. doi: 10.1200/JCO.20.00979 PubMed DOI PMC

Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, et al. . Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. a campus CLL study. Am J Hematol (2021) 96:E168–E71. doi: 10.1002/ajh.26127 PubMed DOI

Molica S, Baumann T, Giannarelli D. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis. Eur J Haematol (2021) 106:425–7. doi: 10.1111/ejh.13548 PubMed DOI

Dreger P, Ghia P, Schetelig J, van Gelder M, Kimby E, Michallet M, et al. . High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies. Blood (2018) 132:892–902. doi: 10.1182/blood-2018-01-826008 PubMed DOI

Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, et al. . Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun (2018) 9:727. doi: 10.1038/s41467-018-03170-7 PubMed DOI PMC

Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. . Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood (2013) 122:2673–82. doi: 10.1182/blood-2013-03-489518 PubMed DOI

Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. . Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med (2013) 210:2273–88. doi: 10.1084/jem.20131448 PubMed DOI PMC

Agathangelidis A, Darzentas N, Hadzidimitriou A, Brochet X, Murray F, Yan XJ, et al. . Stereotyped b-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood (2012) 119:4467–75. doi: 10.1182/blood-2011-11-393694 PubMed DOI PMC

Kwok M, Wu CJ. Clonal evolution of high-risk chronic lymphocytic leukemia: A contemporary perspective. Front Oncol (2021) 11:790004. doi: 10.3389/fonc.2021.790004 PubMed DOI PMC

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. . Resistance mechanisms for the bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 370:2286–94. doi: 10.1056/NEJMoa1400029 PubMed DOI PMC

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. . Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol (2015) 1:80–7. doi: 10.1001/jamaoncol.2014.218 PubMed DOI PMC

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. . BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol (2017) 35:1437–43. doi: 10.1200/JCO.2016.70.2282 PubMed DOI PMC

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. . Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia. Cancer Discovery (2019) 9:342–53. doi: 10.1158/2159-8290.CD-18-1119 PubMed DOI

Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, et al. . Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica (2019) 104:e434–e7. doi: 10.3324/haematol.2019.222588 PubMed DOI PMC

Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, et al. . Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet (2022) 54:1664–74. doi: 10.1038/s41588-022-01140-w PubMed DOI PMC

Hallek M, Pflug N. Chronic lymphocytic leukemia. Ann Oncol (2010) 21(Suppl 7):vii154–64. doi: 10.1093/annonc/mdq373 PubMed DOI

Molica S. Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment. Leuk Lymphoma (1994) 13:203–14. doi: 10.3109/10428199409056283 PubMed DOI

Hilal T, Gea-Banacloche JC, Leis JF. Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. Blood Rev (2018) 32:387–99. doi: 10.1016/j.blre.2018.03.004 PubMed DOI

Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc (2000) 75:1039–54. doi: 10.4065/75.10.1039 PubMed DOI

Roeker LE, Knorr DA, Thompson MC, Nivar M, Lebowitz S, Peters N, et al. . COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia (2021) 35:2703–5. doi: 10.1038/s41375-021-01270-w PubMed DOI PMC

Shen Y, Freeman JA, Holland J, Solterbeck A, Naidu K, Soosapilla A, et al. . COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal b-lymphocytosis; humoural and cellular immunity. Br J Haematol (2022) 197:41–51. doi: 10.1111/bjh.18014 PubMed DOI

Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. . Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood (2022) 139:678–85. doi: 10.1182/blood.2021014085 PubMed DOI PMC